Calreticulin is an effective immunologic adjuvant to tumor‑associated antigens
- Authors:
- Published online on: August 22, 2017 https://doi.org/10.3892/etm.2017.4989
- Pages: 3399-3406
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
As a key molecule involved in cell recognition, calreticulin (CRT) may be expressed on the surface of (pre‑) apoptotic cells and provide the signal that is recognized by dendritic cells (DCs) or other antigen presenting cells (APCs), which results in phagocytosis. Within the APCs, tumor‑associated antigens (TAAs) may be subsequently presented to T lymphocytes, which triggers a specific antitumor immune response. It has been hypothesized that CRT is able to act as the immunologic adjuvant and translocate itself and TAAs to the cell surface and induce a specific antitumor immune response. In the present study, CRT was demonstrated to translocate itself and mucin 1 (MUC1), a breast cancer antigen, to the surface of 4T1 cells and the MUC1‑CRT‑coated cells were able to induce apoptosis in a time‑dependent manner. When DCs were infected with adenovirus containing MUC1‑CRT, an increase in T cell proliferation and cytokine production was exhibited. These results suggest that CRT may act as an immunologic adjuvant with MUC1 and induce a strong immune response.